Vertex Reports ALYFTREK Reverses Pancreatic Damage in Young Cystic Fibrosis Patients

  • Vertex presented interim data showing ALYFTREK restored pancreatic function in 48.6% of 2-5 year old CF patients, allowing some to discontinue pancreatic enzyme replacement therapy.
  • 37.5% of eligible patients successfully discontinued PERT for an average of 8.6 weeks.
  • Data was presented at the North American Cystic Fibrosis Conference (NACFC) in Atlanta, Georgia.
  • ALYFTREK's use in children 2-5 years old is currently investigational.

Vertex's findings challenge the long-held belief that pancreatic damage in cystic fibrosis is irreversible, potentially expanding the treatment window for younger patients. This could position ALYFTREK as a first-line therapy for early-stage CF, addressing a significant unmet need in pediatric care. The data also reinforces Vertex's leadership in CFTR modulator development, maintaining its competitive edge in the cystic fibrosis treatment landscape.

Regulatory Pathway
Whether Vertex can secure approval for ALYFTREK in younger age groups based on these interim results.
Competitive Positioning
How this data positions ALYFTREK against existing CF treatments in the pediatric market.
Long-term Efficacy
The durability of pancreatic function recovery in these young patients over extended treatment periods.